TALEN

TALEN1-apoc2

ID
ZDB-TALEN-151102-2
Name
TALEN1-apoc2
Previous Names
None
Target
Target Sequence 1
5' - ACTATGACCAGAGTGT - 3'
ZFIN BLAST NCBI BLAST Ensembl
Target Sequence 2
5' - AGCCCTTGATGGTCTCT - 3'
ZFIN BLAST NCBI BLAST Ensembl
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
sd38 apoc2
sd39 apoc2
Expression
Gene expression in Wild Types + TALEN1-apoc2
No data available
Phenotype
Phenotype resulting from TALEN1-apoc2
No data available
Phenotype of all Fish created by or utilizing TALEN1-apoc2
Phenotype Fish Conditions Figures
anatomical structure triglyceride increased amount, abnormal apoc2sd38/sd38 control Fig. 4 with image,  Fig. 5 with image,  Fig. 6 with image,  Fig. 7 with image from Liu et al., 2015
ball increased diameter, abnormal apoc2sd38/sd38 standard conditions Fig. 3 with image from Liu et al., 2015
blood plasma high-density lipoprotein decreased amount, abnormal apoc2sd38/sd38 standard conditions Fig. 2 with image from Liu et al., 2015
whole organism decreased length, abnormal apoc2sd38/sd38 standard conditions Fig. 3 with image from Liu et al., 2015
trunk vasculature lipid increased amount, abnormal apoc2sd38/sd38 control Fig. 7 with image from Liu et al., 2015
blood plasma very-low-density lipoprotein increased amount, abnormal apoc2sd38/sd38 standard conditions Fig. 2 with image from Liu et al., 2015
anatomical structure cholesterol increased amount, abnormal apoc2sd38/sd38 control Fig. 4 with image,  Fig. 5 with image,  Fig. 6 with image,  Fig. 7 with image from Liu et al., 2015
blood plasma low-density lipoprotein increased amount, abnormal apoc2sd38/sd38 standard conditions Fig. 2 with image from Liu et al., 2015
blood plasma triglyceride increased amount, abnormal apoc2sd38/sd38 standard conditions Fig. 2 from Liu et al., 2017
extension decreased length, abnormal apoc2sd38/sd38 standard conditions Fig. 3 with image from Liu et al., 2015
thymus rag1 expression decreased amount, abnormal apoc2sd38/sd38 (AB) control Fig. 3 with image from Liu et al., 2018
blood cell hemoglobin decreased amount, abnormal apoc2sd38/sd38 (AB) control Fig. 1 with image from Liu et al., 2018
blood cell decreased amount, abnormal apoc2sd38/sd38 (AB) low fat Fig. 1 with image from Liu et al., 2018
caudal hematopoietic tissue erythroblast hbbe1.1 expression amount, ameliorated apoc2sd38/sd38 (AB) chemical treatment by injection: docosahexaenoic acid Fig. 7 with image from Liu et al., 2018
blood cell decreased amount, abnormal apoc2sd38/sd38 (AB) control Fig. 1 with image,  Fig. 2 with image from Liu et al., 2018
caudal hematopoietic tissue hematopoietic multipotent progenitor cell runx1 expression decreased amount, abnormal apoc2sd38/sd38 (AB) chemical treatment by injection: low-density lipoprotein Fig. 4 with image from Liu et al., 2018
caudal hematopoietic tissue hematopoietic multipotent progenitor cell myb expression decreased amount, abnormal apoc2sd38/sd38 (AB) chemical treatment by injection: icosapentaenoic acid Fig. 7 with image from Liu et al., 2018
blood plasma triglyceride increased amount, abnormal apoc2sd38/sd38 (AB) control Fig. 2 with image from Liu et al., 2018
caudal hematopoietic tissue hematopoietic multipotent progenitor cell myb expression amount, ameliorated apoc2sd38/sd38 (AB) chemical treatment by injection: docosahexaenoic acid Fig. 7 with image from Liu et al., 2018
whole organism lpla expression increased amount, abnormal apoc2sd38/sd38 (AB) control Fig. 2 with image from Liu et al., 2018
caudal vein blood cell decreased amount, abnormal apoc2sd38/sd38 (AB) control Fig. 1 with image,  Fig. 2 with image,  Fig. 4 with image,  Fig. 7 with image from Liu et al., 2018
caudal hematopoietic tissue hematopoietic multipotent progenitor cell runx1 expression amount, ameliorated apoc2sd38/sd38 (AB) chemical treatment by injection: very-low-density lipoprotein Fig. 4 with image from Liu et al., 2018
liver apoa1a expression decreased amount, abnormal apoc2sd38/sd38 (AB) standard conditions Fig. 3 with image from Liu et al., 2017
caudal hematopoietic tissue erythroblast hbbe1.1 expression decreased amount, abnormal apoc2sd38/sd38 (AB) control Fig. 4 with image,  Fig. 7 with image from Liu et al., 2018
hematopoietic multipotent progenitor cell runx1 expression decreased amount, abnormal apoc2sd38/sd38 (AB) control Fig. 3 with image from Liu et al., 2018
caudal hematopoietic tissue hematopoietic multipotent progenitor cell myb expression decreased amount, abnormal apoc2sd38/sd38 (AB) chemical treatment by injection: oleic acid Fig. 7 with image from Liu et al., 2018
whole organism docosahexaenoic acid decreased amount, abnormal apoc2sd38/sd38 (AB) control Fig. 6 from Liu et al., 2018
caudal hematopoietic tissue hematopoietic multipotent progenitor cell runx1 expression decreased amount, abnormal apoc2sd38/sd38 (AB) control Fig. 4 with image,  Fig. 7 with image from Liu et al., 2018
blood plasma triglyceride amount, ameliorated apoc2sd38/sd38 (AB) low fat Fig. 2 from Liu et al., 2017
caudal hematopoietic tissue hematopoietic multipotent progenitor cell myb expression amount, ameliorated apoc2sd38/sd38 (AB) chemical treatment by injection: very-low-density lipoprotein Fig. 4 with image from Liu et al., 2018
whole organism hemoglobin decreased amount, abnormal apoc2sd38/sd38 (AB) control Fig. 1 with image,  Fig. 2 with image,  Fig. 7 with image from Liu et al., 2018
blood cell decreased amount, abnormal apoc2sd38/sd38 (AB) chemical treatment: lomitapide Fig. 1 with image from Liu et al., 2018
erythroblast hbbe1.1 expression decreased amount, abnormal apoc2sd38/sd38 (AB) control Fig. 3 with image from Liu et al., 2018
liver lcat expression decreased amount, abnormal apoc2sd38/sd38 (AB) standard conditions Fig. 3 with image from Liu et al., 2017
caudal hematopoietic tissue hematopoietic multipotent progenitor cell runx1 expression decreased amount, abnormal apoc2sd38/sd38 (AB) chemical treatment by injection: icosapentaenoic acid Fig. 7 with image from Liu et al., 2018
whole organism lipid amount, ameliorated apoc2sd38/sd38 (AB) chemical treatment: lomitapide Fig. 1 with image from Liu et al., 2018
intestine lipid increased amount, abnormal apoc2sd38/sd38 (AB) control Fig. 1 with image from Liu et al., 2018
caudal hematopoietic tissue erythroblast hbbe1.1 expression decreased amount, abnormal apoc2sd38/sd38 (AB) chemical treatment by injection: oleic acid Fig. 7 with image from Liu et al., 2018
caudal vein blood cell decreased amount, abnormal apoc2sd38/sd38 (AB) chemical treatment by injection: icosapentaenoic acid Fig. 7 with image from Liu et al., 2018
blood plasma triglyceride increased amount, abnormal apoc2sd38/sd38 (AB) standard conditions Fig. 1 from Liu et al., 2017
hematopoietic multipotent progenitor cell myb expression decreased amount, abnormal apoc2sd38/sd38 (AB) control Fig. 3 with image from Liu et al., 2018
whole organism hemoglobin decreased amount, abnormal apoc2sd38/sd38 (AB) chemical treatment by injection: icosapentaenoic acid Fig. 7 with image from Liu et al., 2018
caudal hematopoietic tissue hematopoietic multipotent progenitor cell myb expression decreased amount, abnormal apoc2sd38/sd38 (AB) control Fig. 4 with image,  Fig. 7 with image from Liu et al., 2018
blood plasma cholesterol increased amount, abnormal apoc2sd38/sd38 (AB) standard conditions Fig. 1 from Liu et al., 2017
blood plasma cholesteryl ester increased amount, abnormal apoc2sd38/sd38 (AB) standard conditions Fig. 1 from Liu et al., 2017
caudal hematopoietic tissue hematopoietic multipotent progenitor cell myb expression decreased amount, abnormal apoc2sd38/sd38 (AB) low fat Fig. 4 with image from Liu et al., 2018
whole organism hemoglobin decreased amount, abnormal apoc2sd38/sd38 (AB) chemical treatment by injection: oleic acid Fig. 7 with image from Liu et al., 2018
caudal hematopoietic tissue hematopoietic multipotent progenitor cell runx1 expression decreased amount, abnormal apoc2sd38/sd38 (AB) chemical treatment by injection: oleic acid Fig. 7 with image from Liu et al., 2018
caudal hematopoietic tissue erythroblast hbbe1.1 expression decreased amount, abnormal apoc2sd38/sd38 (AB) low fat Fig. 4 with image from Liu et al., 2018
caudal vein blood cell decreased amount, abnormal apoc2sd38/sd38 (AB) chemical treatment by injection: oleic acid Fig. 7 with image from Liu et al., 2018
whole organism lipid increased amount, abnormal apoc2sd38/sd38 (AB) control Fig. 1 with image,  Fig. 4 with image,  Fig. S3 with image from Liu et al., 2018
caudal hematopoietic tissue erythroblast hbbe1.1 expression amount, ameliorated apoc2sd38/sd38 (AB) chemical treatment by injection: very-low-density lipoprotein Fig. 4 with image from Liu et al., 2018
blood plasma cholesterol amount, ameliorated apoc2sd38/sd38 (AB) low fat Fig. 2 from Liu et al., 2017
caudal hematopoietic tissue erythroblast hbbe1.1 expression decreased amount, abnormal apoc2sd38/sd38 (AB) chemical treatment by injection: icosapentaenoic acid Fig. 7 with image from Liu et al., 2018
whole organism lcat expression decreased amount, abnormal apoc2sd38/sd38 (AB) standard conditions Fig. 3 with image from Liu et al., 2017
thymus lymphocyte rag1 expression decreased amount, abnormal apoc2sd38/sd38 (AB) control Fig. 3 with image from Liu et al., 2018
caudal hematopoietic tissue hematopoietic multipotent progenitor cell runx1 expression amount, ameliorated apoc2sd38/sd38 (AB) chemical treatment by injection: docosahexaenoic acid Fig. 7 with image from Liu et al., 2018
erythroblast increased amount, abnormal apoc2sd38/sd38 (AB) control Fig. 1 with image from Liu et al., 2018
macrophage lipid increased amount, abnormal apoc2sd38/sd38; gl22Tg standard conditions Fig. 7 with image from Liu et al., 2015
pancreas growth growth quality of occurrent, abnormal apoc2sd38/sd38; jh1Tg standard conditions Fig. 8 with image from Liu et al., 2015
pancreas morphology, abnormal apoc2sd38/sd38; jh1Tg standard conditions Fig. 8 with image from Liu et al., 2015
pancreas growth increased process quality, abnormal apoc2sd38/sd38; jh1Tg standard conditions Fig. 8 with image from Liu et al., 2015
thymus hematopoietic multipotent progenitor cell decreased amount, abnormal apoc2sd38/sd38; la2Tg control Fig. 3 with image from Liu et al., 2018
caudal hematopoietic tissue hematopoietic multipotent progenitor cell decreased amount, abnormal apoc2sd38/sd38; la2Tg control Fig. 3 with image from Liu et al., 2018
intersegmental vessel angiogenesis delayed, abnormal apoc2sd38/sd38; y1Tg standard conditions Fig. 3 with image from Liu et al., 2015
subintestinal vein angiogenesis delayed, abnormal apoc2sd38/sd38; y1Tg standard conditions Fig. 3 with image from Liu et al., 2015
whole organism intermediate-density lipoprotein decreased amount, abnormal apobb.1c832Tg/+; apoc2sd38/sd38 (AB) standard conditions Fig. 3 from Thierer et al., 2019
whole organism low-density lipoprotein decreased amount, abnormal apobb.1c832Tg/+; apoc2sd38/sd38 (AB) standard conditions Fig. 3 from Thierer et al., 2019
whole organism very-low-density lipoprotein increased amount, abnormal apobb.1c832Tg/+; apoc2sd38/sd38 (AB) standard conditions Fig. 3 from Thierer et al., 2019
whole organism Luciferase expression increased amount, abnormal apobb.1c832Tg/+; apoc2sd38/sd38 (AB) standard conditions Fig. 2,  Fig. 5 with image from Thierer et al., 2019
Citations
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.